Primary sclerosing cholangitis: Surgical options, prognostic variables and outcome

Author:

Ismail T1,Angrisani L1,Powell J E2,Hübscher S3,Buckels J1,Neuberger J1,Elias E1,McMaster P1

Affiliation:

1. The Liver Unit, Queen Elizabeth Hospital, University of Birmingham, Birmingham, UK

2. Department of Statistics, University of Birmingham, Birmingham, UK

3. Department of Pathology, University of Birmingham, Birmingham, UK

Abstract

Abstract The natural history of primary sclerosing cholangitis (PSC) is poorly defined and its management remains controversial. Forty-eight symptomatic patients (median age 39 years, range 8–67 years; 30 male) with PSC were reviewed retrospectively. Thirty patients had inflammatory bowel disease. Four patients (8 per cent) developed or had an associated malignancy. Twenty-one (44 per cent) died; overall 5 year actuarial survival was 30 per cent. Twenty-three patients had 27 non-transplant related biliary operations (16 patients specifically for PSC) of whom 12 died. Serum bilirubin was the only parameter to improve after biliary surgery. Seventeen patients (35 per cent) underwent orthotopic liver transplanation (OLT) of whom nine are currently alive (1 year projected survival of 55 per cent). Previous biliary surgery correlated with a poor outcome (P < 0.0001) after OLT. Being male, presence of cirrhosis, duration of symptomatic disease (> 3 years) and a serum bilirubin level > 100 μmol/l at presentation, were independently associated with a poor outcome (P < 0.05). These data provide evidence that PSC is a progressive disease and conventional surgical options have little influence on the outcome. Previous biliary surgery adversely affects outcome following OLT. For progressive liver disease, liver transplantation should be considered the treatment of choice.

Publisher

Oxford University Press (OUP)

Subject

Surgery

Reference21 articles.

1. Primary sclerosing cholangitis;Summerfield;Postgrad Med J,1983

2. Retrecissement du choledoque: cholecystoduo-denostomie;Delbet;Bull Mem Soc Nat Chirurg,1924

3. Azathioprine treatment in primary sclerosing cholangitis;Wagner;Lancet,1971

4. Primary sclerosing cholangitis: complete gross and histologic reversal after long-term steroid therapy;Myers;Am J Gastroenterol,1970

5. Beneficial effect of colchicine in a case of sclerosing cholangitis;Leiser;Am J Med Sci,1986

Cited by 65 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Clinical guidelines for primary sclerosing cholangitis 2017;Journal of Gastroenterology;2018-06-27

2. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan;Journal of Hepato-Biliary-Pancreatic Sciences;2017-03-04

3. Liver transplantation;Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set;2017

4. Malignancy and Primary Sclerosing Cholangitis: Cholangiocarcinoma, Hepatocellular Carcinoma, and Gallbladder Carcinoma;Primary Sclerosing Cholangitis;2016-11-13

5. When Is Bile Duct Resection Indicated for Biliary Strictures in Primary Sclerosing Cholangitis?;Difficult Decisions in Surgery: An Evidence-Based Approach;2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3